There is an ongoing discussion on potential prognostic value of assessment of right ventricular dysfunction (RVD) in low risk patients with acute pulmonary embolism (PE) who are are candidates for home treatment or short-hospital stay. Dr Becattini tried to solve this challenge and aimed at determining whether the RVD assessment or elevated troponin improves identification of low-risk patients over clinical models alone. Thereore, they performend very elegant meta-analysis of pooled individual patient (IPDMA) data of >5000 subjects included into 18 studies assessing the relationship between RVD or elevated troponin and shortterm mortality in patients with acute PE at low risk for death based on clinical models (Pulmonary Embolism Severity Index, simplified Pulmonary Embolism Severity Index or Hestia) . The primary outcome of IPDMA was short-term death defined as death occurring in hospital or within 30 days. Short-term mortality was 0.7% [95% CI 0.4–1.3]. RVD at echocardiography, computed tomography or B-type natriuretic peptide was associated with increased risk for short-term death (1.5 vs. 0.3%; OR 4.81, 95% CI 1.98–11.68), death within 3 months and PE-related death (1.1 vs. 0.04%; OR 22.9, 95% CI 2.89–181). Interestingly, RVD at echocardiography and BNP or NT-proBNP levels were the most reliable predictors of death in low rsik PE patients. Indeed, this study can help clinicians in decision making, beacuse RVD assessment, mainly by BNP/NT-proBNP or echocardiography, should improve identification of low-risk PE patients and facilitate their outpatient management or short hospital stay.